Marshall Edwards, Inc.

Preliminary ovarian cancer phase IIa trial results released

Published in Hospital Business Week, June 12th, 2005

Marshall Edwards, Inc., (MSHL) released preliminary results from a phase IIa trial in patients with ovarian cancer that has demonstrated resistance to the standard first-line chemotherapies of cisplatin and/or paclitaxel.

In this trial, the investigational drug phenoxodiol (PXD) is being administered in conjunction with cisplatin or paclitaxel in an attempt to reverse the acquired resistance of the tumors to those two drugs. Phenoxodiol has not been approved for marketing.

The multicenter trial is being conducted at the Yale - New Haven Hospital, New Haven, Conn., and at the Royal Women's Hospital, Melbourne, Australia.

Enrolment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Business Week

Source: Hospital Business Week (2005-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry